Management of laryngeal chondroradionecrosis: A single-center experience.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-08-13 DOI:10.1002/hed.27919

Einav G Levin, Amit Ritter, Gideon Bachar, Aviram Mizrachi, Hagit Shoffel-Havakuk, Noga Kurman, Aron Popovtzer, Yaniv Hamzany

{"title":"Management of laryngeal chondroradionecrosis: A single-center experience.","authors":"Einav G Levin, Amit Ritter, Gideon Bachar, Aviram Mizrachi, Hagit Shoffel-Havakuk, Noga Kurman, Aron Popovtzer, Yaniv Hamzany","doi":"10.1002/hed.27919","DOIUrl":null,"url":null,"abstract":"Background: Laryngeal chondroradionecrosis (LCRN) is a rare but severe complication of radiation therapy. The study aimed to review the management of LCRN and evaluate the clinical benefit of hyperbaric oxygen therapy (HBOT).Methods: We retrospectively analyzed all radiation-induced LCRN patients between 2006 and 2019 at a tertiary medical center. Diagnosis was based on signs and symptoms of Chandler's classification, imaging, and/or histopathology report. The primary outcome was improvement in Chandler's grade after HBOT.Results: Of 678 irradiated laryngeal cancer patients, 29 (4.3%) were diagnosed with LCRN. The most common primary management was tracheostomy with intravenous steroids and antibiotics (59%). Ten patients received HBOT (34.5%), and six underwent total laryngectomy (21%). In HBOT-treated patients, Chandler's grade significantly improved from a median of 4 (range 2-4) to 2.5 (range 1-4; p = 0.005).Conclusions: HBOT may benefit in the management of patients with persistence and unresponsive symptoms of LCRN following radiation therapy for laryngeal SCC.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.27919","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Laryngeal chondroradionecrosis (LCRN) is a rare but severe complication of radiation therapy. The study aimed to review the management of LCRN and evaluate the clinical benefit of hyperbaric oxygen therapy (HBOT).

Methods: We retrospectively analyzed all radiation-induced LCRN patients between 2006 and 2019 at a tertiary medical center. Diagnosis was based on signs and symptoms of Chandler's classification, imaging, and/or histopathology report. The primary outcome was improvement in Chandler's grade after HBOT.

Results: Of 678 irradiated laryngeal cancer patients, 29 (4.3%) were diagnosed with LCRN. The most common primary management was tracheostomy with intravenous steroids and antibiotics (59%). Ten patients received HBOT (34.5%), and six underwent total laryngectomy (21%). In HBOT-treated patients, Chandler's grade significantly improved from a median of 4 (range 2-4) to 2.5 (range 1-4; p = 0.005).

Conclusions: HBOT may benefit in the management of patients with persistence and unresponsive symptoms of LCRN following radiation therapy for laryngeal SCC.

查看原文本刊更多论文

喉软骨软化症的治疗：单中心经验

背景：喉软骨软化症（LCRN）是放疗的一种罕见但严重的并发症。本研究旨在回顾LCRN的治疗方法，并评估高压氧治疗（HBOT）的临床益处：我们回顾性分析了一家三级医疗中心在 2006 年至 2019 年期间所有由放射治疗引发的 LCRN 患者。诊断依据是钱德勒分类的体征和症状、影像学和/或组织病理学报告。主要结果是 HBOT 后钱德勒分级的改善情况：结果：在678名接受过放射治疗的喉癌患者中，29人（4.3%）被诊断为LCRN。最常见的主要治疗方法是气管造口术，同时静脉注射类固醇和抗生素（59%）。10名患者接受了HBOT治疗（34.5%），6名患者接受了全喉切除术（21%）。在接受过 HBOT 治疗的患者中，钱德勒评分从中位数 4（范围 2-4）明显降低到 2.5（范围 1-4；P = 0.005）：HBOT可用于治疗喉SCC放疗后LCRN症状持续存在且无反应的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464